# EDGAR Filing Document

**Accession Number:** 0001538495
**File Stem:** 0001493152-26-029200
**Filing Date:** 2026-6
**Character Count:** 14645
**Document Hash:** 92396614edb33ddf09d8c2a695524959
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-029200.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001493152-26-029200

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260618

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Earth Science Tech, Inc.
- **CENTRAL INDEX KEY:** 0001538495
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 454267181
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55000
- **FILM NUMBER:** 261100520

**BUSINESS ADDRESS:**
- **STREET 1:** 8950 SW 74TH CT
- **STREET 2:** SUITE 101
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33156
- **BUSINESS PHONE:** (786) 375-7281

**MAIL ADDRESS:**
- **STREET 1:** 8950 SW 74TH CT
- **STREET 2:** SUITE 101
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33156

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ultimate Novelty Sports Inc.
- **DATE OF NAME CHANGE:** 20111230

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 18, 2026**

Commission File No. 000-55000

**<u>EARTH SCIENCE TECH, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **florida** | **45-4267181** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**<u>8950 SW 74th CT</u>**

**<u>Suite 1401</u>**

**<u>Miami, FL 33156, USA</u>**

(Address of principal executive offices, zip code)

**<u>(305) 724-5684</u>**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(g) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock $0.001 par value | ETST | Over the Counter Bulletin Board |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition**

On June 18, 2026, the Company issued a press release (the "Release") reporting its fiscal year-end financial results for March 31, 2026.

A copy of the Release issued by the Company on June 18, 2026, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits* – The following exhibits are filed as part of this report:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release issued by the registrant on June 18, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EARTH SCIENCE TECH, INC.** | **EARTH SCIENCE TECH, INC.** |
| **Dated: June 18, 2026** | **By:** | ***/s/ Giorgio R. Saumat*** |
|  |  | Giorgio R. Saumat |
|  | **Its:** | **CEO and Chairman of the Board** |

---

## Exhibit 99.1

**Exhibit 99.1**

**Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026**

**MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Earth Science Tech, Inc.** (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial results for the full fiscal year ended March 31, 2026.

"Our fiscal 2026 results reflect the meaningful progress we have made over the last several years to build a business that is durable, self-sustaining and positioned for long-term growth," said Giorgio R. Saumat, CEO and Chairman of the Board of Earth Science Tech, Inc. "In fiscal 2026, we grew revenue, increased earnings, generated positive operating cash flow and strengthened our balance sheet, all while not adding debt to our balance sheet. These results are driven by the work we have done to better integrate the patient experience across our platform, from telemedicine to pharmacy to fulfillment. By owning more of that process, we serve patients effectively while building a stronger and more profitable business."

Mr. Saumat continued, "We delivered these results while remaining disciplined with our capital. During fiscal 2026 and subsequent to year end, we repurchased and retired more than 7.1 million shares of common stock, continued investing in new products and expanded the reach of our healthcare platform. We believe we are still in the early stages of what this business can become. Fiscal year-end 2026 laid the essential foundation for what management foresees as our next leg of growth, and this trajectory is already showing in fiscal Q1 2027. By continuing our aggressive share buyback program—purchasing over 3.1 million shares in the first quarter of fiscal 2027 alone—we are actively creating lasting value for our shareholders. The upcoming report for the quarter ending June 30, 2026, will clearly show how the foundation laid out during fiscal 2026 is transpiring and moving forward. We remain focused on executing the same strategy that has brought us to this point by growing responsibly and investing for the future."

<u>For the fiscal year ended March 31, 2026, the Company reported the following results</u>:

● **Revenue:** $35.7 million, up 8% compared to $33.1 million for the 12 months ended March 31, 2025.

● **Gross profit:** $25.5 million, up 5% compared to $24.3 million for the 12 months ended March 31, 2025.

● **Net income:** $3.6 million, up 11% compared to $3.3 million for the 12 months ended March 31, 2025.

● **Total Assets:** $9.0 million, up 27% compared to $7.1 million at March 31, 2025.

● **Repurchased and retired shares:** 4,023,296 shares of common stock for the 12 months ended March 31, 2026.

**About Earth Science Tech, Inc. (ETST)**

Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company's principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.

To learn more, please visit: <u>www.EarthScienceTech.com</u>

**Forward-Looking Statements**

Except for historical information, the matters discussed herein may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.

Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as "expect," "expectation," "believe," "anticipate," "may," "could," "intend," "belief," "plan," "estimate," "target," "predict," "likely," "seek," "project," "model," "ongoing," "will," "should," "forecast," "outlook" or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

**Company Contact:**

Giorgio R. Saumat

CEO and Chairman of the Board

(305) 724-5684

<u>IR@earthsciencetech.com</u>

**— Tables Follow –**

**Earth Science Tech, Inc. and Subsidiaries**

**Consolidated Balance Sheets**

**as of March 31, 2026, and 2025**

---

| | | |
|:---|:---|:---|
|  | **As of March 31,** | **As of March 31,** |
|  | **2026** | **2025** |
| **ASSETS:** |  |  |
| **Current Assets** |  |  |
| Cash and cash equivalents | $796797 | $1473228 |
| Accounts receivable, net | 356054 | 129064 |
| Equity securities | 1360040 | 645438 |
| Inventory | 682059 | 503938 |
| Long lived assets, available for sale | 371684 |  |
| Prepaid Expenses and other current assets | 154480 | 358837 |
| **Total Current Assets** | **3721114** | **3110505** |
| **Non-Current Assets** |  |  |
| Property and Equipment, net | 1517888 | 1384110 |
| Right of use assets, net | 95317 | 172429 |
| Intangible assets, net | 208170 | 96885 |
| Deferred tax asset, net | 772294 |  |
| Goodwill | 2654554 | 2302792 |
| **TOTAL ASSETS** | $**8969337** | $**7066721** |
| **<u>LIABILITIES AND EQUITY:</u>** |  |  |
| **Current Liabilities** |  |  |
| Accounts payable | $681925 | $492352 |
| Accrued expenses and other payables | 1150442 | 2322022 |
| Current portion of operating lease obligations | 96206 | 121851 |
| Current portion of loans & obligations |  | 30592 |
| Short-term business loans |  | 179488 |
| **Total Current Liabilities** | **1928573** | **3146305** |
| **Long-Term Liabilities** |  |  |
| Lease Liability |  | 37878 |
| Loans and Obligations | - | 31427 |
| **Total Liabilities** | **1928573** | **3215610** |
| **Commitments and Contingencies (Note 11)** |  |  |
| **Stockholders' Equity** |  |  |
| **Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively** | 1000 | 1000 |
| **Common stock, par value $0.001 per share, 300,000,000 shares authorized; 291,324,607 shares issued and outstanding as of March 31, 2026, and 295,347,903 issued and 294,302,607 outstanding as of March 31, 2025** | 291324 | 295348 |
| **Additional Paid in Capital** | 30826352 | 31480143 |
| **Accumulated Deficit** | (24108199) | (27738975) |
| **Treasury Stock, at cost (0 and 1,045,296 shares as of March 31, 2026, and March 31, 2025, respectively)** | - | (186405) |
| **Total Stockholders' Equity** | **7010477** | **3851111** |
| **Non-Controlling Interest** | **30287** | **-** |
| **Total Equity** | **7040764** | **3851111** |
| **TOTAL LIABILITIES AND EQUITY** | $**8969337** | $**7066721** |

---

The accompanying notes are an integral part of these consolidated financial statements.

**Earth Science Tech, Inc. and Subsidiaries**

**Consolidated Statements of Operations**

**For Years Ended March 31, 2026, and 2025**

---

| | | |
|:---|:---|:---|
|  | **2026** | **2025** |
| **Revenue** | $35695614 | $33117624 |
| **Cost of Goods Sold** | 10207557 | 8817488 |
| **Gross Profit** | **25488057** | **24300136** |
| **Expenses** |  |  |
| **Salaries Expense** | 13776033 | 14115643 |
| **Selling general and administrative expenses** | 3571448 | 4154838 |
| **Bank charges** | 1006026 | 1066577 |
| **Advertising & marketing** | 2840553 | 836860 |
| **Legal and professional fees** | 221179 | 305932 |
| **Insurance** | 168353 | 180281 |
| **Operating lease cost** | 180753 | 98434 |
| **Depreciation and amortization** | 284396 | 53951 |
| **Utilities** | 130790 | 39661 |
| **Total Expenses** | $**22179531** | $**20852178** |
| **Other income (expense)** |  |  |
| **Dividend and interest income** | 15458 | 9141 |
| **Net realized gain on sale of investments** | 671528 | 300162 |
| **Unrealized Gain (Loss) on fair value changes of investments** | (957118) | (365661) |
| **Other** | 67194 |  |
| **Interest Expense** | (16327) | (21189) |
| **Net Income before taxes** | **3089261** | **3370411** |
| **Income Taxes** | (511676) | 116776 |
| **Net Income** | $**3600937** | $**3253635** |
| **Net Income/(Loss) attributed to non-controlling interest** | (29839) |  |
| **Net Income available to common stockholders'** | **3630776** | **3253635** |
| **Earnings per common share-Basic and Diluted** | $**0.012** | $**0.011** |
| Weighted average number of shares outstanding- Basic and Diluted | 293069803 | 303521458 |

---

The accompanying notes are an integral part of these consolidated financial statements.